Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

843 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Variants of the interferon regulatory factor 5 gene regulate expression of IRF5 mRNA in atherosclerotic tissue but are not associated with myocardial infarction.
Mälarstig A, Sigurdsson S, Eriksson P, Paulsson-Berne G, Hedin U, Wallentin L, Siegbahn A, Hamsten A, Syvänen AC. Mälarstig A, et al. Among authors: wallentin l. Arterioscler Thromb Vasc Biol. 2008 May;28(5):975-82. doi: 10.1161/ATVBAHA.108.163733. Epub 2008 Mar 6. Arterioscler Thromb Vasc Biol. 2008. PMID: 18323517
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
Wallentin L, Bergstrand L, Dellborg M, Fellenius C, Granger CB, Lindahl B, Lins LE, Nilsson T, Pehrsson K, Siegbahn A, Swahn E. Wallentin L, et al. Eur Heart J. 2003 May;24(10):897-908. doi: 10.1016/s0195-668x(03)00006-x. Eur Heart J. 2003. PMID: 12714021 Clinical Trial.
N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.
James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L. James SK, et al. Among authors: wallentin l. Circulation. 2003 Jul 22;108(3):275-81. doi: 10.1161/01.CIR.0000079170.10579.DC. Epub 2003 Jul 7. Circulation. 2003. PMID: 12847065 Clinical Trial.
Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.
James SK, Siegbahn A, Armstrong P, Barnathan E, Califf R, Simoons ML, Wallentin L. James SK, et al. Among authors: wallentin l. Am Heart J. 2004 Feb;147(2):267-74. doi: 10.1016/j.ahj.2003.09.014. Am Heart J. 2004. PMID: 14760324 Clinical Trial.
Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes.
Mälarstig A, Tenno T, Johnston N, Lagerqvist B, Axelsson T, Syvänen AC, Wallentin L, Siegbahn A. Mälarstig A, et al. Among authors: wallentin l. Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2667-72. doi: 10.1161/01.ATV.0000191637.48129.9b. Epub 2005 Oct 20. Arterioscler Thromb Vasc Biol. 2005. PMID: 16239598
843 results